GN
Therapeutic Areas
Kamada Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Inhaled AAT (KMA-001) | Alpha-1 Antitrypsin Deficiency (AATD) with emphysema | Phase 3 |
| IV AAT | Graft-Versus-Host Disease (GvHD) | Phase 2 |
| Anti-Rabies IgG (KamRab) | Rabies Post-Exposure Prophylaxis | Marketed |
Leadership Team at Kamada
AL
Amir London
Chief Executive Officer
JB
Joshua Berkman
Senior VP, Corporate Communications & Investor Relations
NG
Nathalie Gordin
Senior VP, Global Human Resources
DE
Dr. Eran Schenker
Chief Medical Officer
ER
Eran Reshef
Senior VP, Global Operations
RK
Roni Klapholz
Senior VP, Global Commercial Operations